Last updated: 10 September 2024 at 6:42pm EST

Paul Mann Net Worth




The estimated Net Worth of Paul Elliot Mann is at least $33.2 Million dollars as of 15 July 2024. Mr. Mann owns over 39,984 units of Abeona Therapeutics Inc stock worth over $32,677,055 and over the last 6 years he sold ABEO stock worth over $561,190. In addition, he makes $0 as Independent Director at Abeona Therapeutics Inc.

Mr. Mann ABEO stock SEC Form 4 insiders trading

Paul has made over 14 trades of the Abeona Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 39,984 units of ABEO stock worth $223,511 on 15 July 2024.

The largest trade he's ever made was selling 132,664 units of Abeona Therapeutics Inc stock on 17 February 2021 worth over $310,434. On average, Paul trades about 14,873 units every 73 days since 2018. As of 15 July 2024 he still owns at least 5,845,627 units of Abeona Therapeutics Inc stock.

You can see the complete history of Mr. Mann stock trades at the bottom of the page.





Paul Mann biography

Paul Elliot Mann serves as Independent Director of the Company. Mr. Mann has over 20 years of experience in the financial and biotechnology industries. Most recently, he served as CFO at PolarityTE, Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that, Mr. Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Procter and Gamble and is named as an inventor on patents for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering.



How old is Paul Mann?

Paul Mann is 43, he's been the Independent Director of Abeona Therapeutics Inc since 2020. There are 6 older and 2 younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.

What's Paul Mann's mailing address?

Paul's mailing address filed with the SEC is C/O ASP ISOTOPES INC., 601 PENNSYLVANIA AVENUE NWSUITE 900, WASHINGTON, DC, DC, 20004.

Insiders trading at Abeona Therapeutics Inc

Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.



What does Abeona Therapeutics Inc do?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t



What does Abeona Therapeutics Inc's logo look like?

Abeona Therapeutics Inc logo

Complete history of Mr. Mann stock trades at Abeona Therapeutics Inc, PolarityTE Inc, and Aspire Real Estate Investors

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Jul 2024 Paul Elliot Mann
Chief Executive Officer
Buy 39,984 $3.83 $153,139
15 Jul 2024
5,845,627
19 Feb 2021 Paul Elliot Mann
Director
Option 45,566 $1.28 $58,324
19 Feb 2021
45,566
17 Feb 2021 Paul Elliot Mann
Director
Sale 132,664 $2.34 $310,434
17 Feb 2021
0
31 Dec 2020 Paul Elliot Mann
Director
Sale 30,488 $1.54 $46,952
31 Dec 2020
132,664
18 Dec 2020 Paul Elliot Mann
Director
Sale 17,079 $1.59 $27,156
18 Dec 2020
772,907
2 Dec 2020 Paul Elliot Mann
Director
Sale 30,488 $1.49 $45,427
2 Dec 2020
789,986
2 Nov 2020 Paul Elliot Mann
Director
Sale 30,488 $1.04 $31,708
2 Nov 2020
820,474
31 Mar 2020 Paul Elliot Mann
Chief Financial Officer
Sale 23,158 $1.04 $24,084
31 Mar 2020
415,953
23 Mar 2020 Paul Elliot Mann
Chief Financial Officer
Sale 1,283 $1.05 $1,347
23 Mar 2020
439,111
7 Feb 2020 Paul Elliot Mann
Chief Financial Officer
Sale 12,833 $3.02 $38,756
7 Feb 2020
440,393
23 Dec 2019 Paul Elliot Mann
Chief Financial Officer
Sale 11,000 $2.71 $29,810
23 Dec 2019
453,227
23 Sep 2019 Paul Elliot Mann
Chief Financial Officer
Sale 1,283 $4.30 $5,517
23 Sep 2019
464,227
5 Jun 2019 Paul Elliot Mann
Chief Financial Officer
Buy 35,000 $5.33 $186,550
5 Jun 2019
156,247
18 Sep 2018 Paul Elliot Mann
Chief Financial Officer
Buy 20,000 $17.24 $344,800
18 Sep 2018
120,000


Abeona Therapeutics Inc executives and stock owners

Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: